BELLEVUE, Wash.--(BUSINESS WIRE)-- Translational Software®, Inc., a leader in the intelligent use of genetic data for clinical decision support and precision medicine, today announced the launch of a drug-drug interaction capability powered by First Databank (FDB), the leading provider of clinical drug knowledge that helps improve medication-related decisions and patient outcomes in the U.S. and Canada. The company has integrated FDB Cloud Connector™, a web service that delivers FDB’s drug-drug interaction content via the cloud, for use with TSI’s pharmacogenetic (PGx) knowledge base and interpretation platform to help clinicians identify and prevent harmful drug interactions and make informed medication decisions for effective patient treatment.
TSI’s PGx portal and knowledge base interprets molecular test results across a variety of complex medical domains to help physicians deliver the highest level of personalized care. The collaboration with FDB allows TSI to integrate raw genetic results data with a single source for both drug-gene and drug-drug information to help clinicians predict potential interactions and adverse drug events when choosing alternative patient therapies. Physicians receive a report and color-coded list of all known medications for which dosing should be personalized on the basis of the patient’s genetic test results, coupled with recommended medication alternatives and dosing guidance.
Don Rule, Translational Software’s CEO stated, “Through our collaboration with FDB, we have incorporated the most clinically significant drug-drug interaction alerts available, making our PGx knowledge base even more actionable to help minimize the risk of adverse interactions and improve the success of treatment outcomes. Working with FDB continues to build on our core mission of helping leading labs and healthcare providers link a patient’s genetic make-up and unique risk factors to specific clinical guidance - all within the clinical workflow.”
FDB’s Drug-Drug Interaction Module™ provides information for prescription and OTC drugs, alternative therapies such as herbals and dietary supplements, and inactive ingredients. Users can configure and manage alerts using severity levels and subcategories. Drug-drug interaction monographs are also incorporated and reference the primary medical literature and government-approved prescribing information.
“When clinicians can be informed at the point of care of ever-changing drug-drug and drug-gene interactions, they can make the most effective, personalized therapeutic decisions that result in better health outcomes at a considerable cost savings to the healthcare system,” stated Chuck Tuchinda, MD, MBA, president, FDB. “We are pleased to be working with Translational Software to expand their comprehensive knowledge base to guide precision medicine initiatives for their customers.”
TSI will be demonstrating the integrated medication alerting solution in the Hearst Health/FDB booth #1143 at the upcoming Health Information Management Systems Society conference and exhibition in Las Vegas, NV, Feb. 29 – March 4.
About Translational Software, Inc.
Translational Software provides end-to-end solutions to support laboratories and healthcare providers adopting personalized medicine. Its powerful PGx portal transforms genomic and molecular data into actionable knowledge, integrating the best available clinical decision support with laboratory and clinical information systems to guide therapeutic options for medication management to enhance patient care. For more information visit www.translationalsoftware.com or follow us on LinkedIn.
About First Databank (FDB)
FDB (First Databank), part of the Hearst Health network, is the leading provider of drug knowledge that helps healthcare professionals make precise medication-related decisions. With thousands of customers worldwide, FDB enables our information system developer partners to deliver a wide range of valuable, useful, and differentiated solutions. As the company that virtually launched the medication decision support category, we offer more than three decades of experience in transforming drug knowledge into actionable, targeted, and effective solutions that improve patient safety and healthcare outcomes. For a complete look at our solutions and services please visit www.fdbhealth.com or follow us on Twitter and LinkedIn.